Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Pharmacokinetic evaluation of axitinib.

Patson B, B Cohen R, Olszanski AJ.

Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):259-70. doi: 10.1517/17425255.2012.652947. Epub 2012 Jan 17. Review.

PMID:
22248343
2.

Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?

Goldstein R, Pickering L, Larkin J.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1545-57. doi: 10.1586/era.10.134. Review.

PMID:
20942625
3.

Axitinib for the treatment of advanced non-small-cell lung cancer.

King JW, Lee SM.

Expert Opin Investig Drugs. 2013 Jun;22(6):765-73. doi: 10.1517/13543784.2013.775243. Epub 2013 Mar 1. Review.

PMID:
23452008
4.

Axitinib (AG-013736).

Kelly RJ, Rixe O.

Recent Results Cancer Res. 2010;184:33-44. doi: 10.1007/978-3-642-01222-8_3. Review.

PMID:
20072829
5.

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.

Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652.

6.

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.

Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE.

Cancer. 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. Epub 2014 May 20.

7.

Axitinib for the treatment of advanced renal cell carcinoma.

Akaza H, Fukuyama T.

Expert Opin Pharmacother. 2014 Feb;15(2):283-97. doi: 10.1517/14656566.2014.868436. Epub 2013 Dec 13. Review.

PMID:
24328549
8.

Axitinib for renal cell carcinoma.

Sonpavde G, Hutson TE, Rini BI.

Expert Opin Investig Drugs. 2008 May;17(5):741-8. doi: 10.1517/13543784.17.5.741 . Review. Erratum in: Expert Opin Investig Drugs. 2008 Sep;17(9):1405.

PMID:
18447599
9.

Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.

Zakharia Y, Zakharia K, Rixe O.

Expert Opin Drug Discov. 2015;10(8):925-35. doi: 10.1517/17460441.2015.1045411. Epub 2015 Jun 3. Review.

PMID:
26039031
10.

Pharmacokinetics of single-agent axitinib across multiple solid tumor types.

Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1279-89. doi: 10.1007/s00280-014-2606-6. Epub 2014 Oct 22.

PMID:
25336084
11.

Axitinib for the management of metastatic renal cell carcinoma.

Escudier B, Gore M.

Drugs R D. 2011;11(2):113-26. doi: 10.2165/11591240-000000000-00000. Review.

12.

Axitinib in metastatic renal cell carcinoma.

Albiges L, Gizzi M, Carton E, Escudier B.

Expert Rev Anticancer Ther. 2015 May;15(5):499-507. doi: 10.1586/14737140.2015.1033408. Review.

PMID:
25907705
13.

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.

Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E, Schmidinger M.

Expert Opin Drug Saf. 2014 Apr;13(4):497-510. doi: 10.1517/14740338.2014.888413. Review.

PMID:
24641566
14.

Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1273-1276. doi: 10.1007/s00280-017-3320-y. Epub 2017 Apr 27.

PMID:
28451830
15.

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J.

J Clin Oncol. 2009 Aug 10;27(23):3836-41. doi: 10.1200/JCO.2008.20.8355. Epub 2009 Jul 13.

PMID:
19597027
16.

Axitinib, a new therapeutic option in renal cell carcinoma.

Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A.

Drugs Today (Barc). 2012 Oct;48(10):633-44. doi: 10.1358/dot.2012.48.10.1860768. Review.

PMID:
23110259
17.

Axitinib in the treatment of metastatic renal cell carcinoma.

Ho TH, Jonasch E.

Future Oncol. 2011 Nov;7(11):1247-53. doi: 10.2217/fon.11.107. Review.

PMID:
22044199
18.

Axitinib plasma pharmacokinetics and ethnic differences.

Chen Y, Suzuki A, Tortorici MA, Garrett M, LaBadie RR, Umeyama Y, Pithavala YK.

Invest New Drugs. 2015 Apr;33(2):521-32. doi: 10.1007/s10637-015-0214-x. Epub 2015 Feb 8. Review.

PMID:
25663295
19.

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.

Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V.

Ann Oncol. 2015 Jul;26(7):1372-7. doi: 10.1093/annonc/mdv103. Epub 2015 Feb 20.

PMID:
25701454
20.

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.

Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. doi: 10.1007/s00280-014-2604-8. Epub 2014 Oct 15.

Supplemental Content

Support Center